Explore the Global Peptide Receptor Radionuclide Therapy (PRRT) Market — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036

Future Market Insights

Peptide Receptor Radionuclide Therapy (PRRT) Market

Key Insight

Peptide receptor radionuclide therapy sales will expand through 2036, with regulatory peptide holding a 35.0% share of the component segment in 2026. Gastrointestinal neuroendocrine tumours lead the application segment with a 42.0% share. The market is set to reach USD 813.3 million by 2026-end and USD 1,838.9 million by 2036.

April 30, 2026

Anurag Sharma

250 Pages

Cite this Report

Peptide Receptor Radionuclide Therapy (PRRT) Market

https://www.futuremarketinsights.com/reports/peptide-receptor-radionuclide-therapy-prrt-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Advanced Accelerator Applications
Curium Pharma
Eckert & Ziegler AG
Fusion Pharmaceuticals Inc
ITM Isotope Technologies Munich SE
Novartis AG

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Peptide Receptor Radionuclide Therapy (PRRT) Market

Key Players

Similar Industry Reports